RxDoctor Payments Data

Matthew Sowle, PA

Physician Assistant · Gulf Shores, ALNPI 1245275510

Payments from drug & device makers

$1,897in general payments, 2019–2025

Across 114 payments — averaging $16.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$408
  • AstraZeneca$285
  • Novo Nordisk$215
  • Johnson & Johnson$132
  • Mylan Specialty L.p.$122
  • Pfizer$94
  • plus $640 from 20 others

What the payments were for

  • Food & beverage$1,897100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,897 in reported general payments places this provider in the 75th percentile of 846 physician assistant providers in Alabama.

See all physician assistant providers in Alabama

Medicare billing

Part B allowed, 2024
$76,866
Medicare patients
460
Services billed
2,106

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide37$48,291
EliquisApixaban24$29,900
FarxigaDapagliflozin Propanediol17$22,167
OzempicSemaglutide14$16,847
Trelegy ElliptaFluticasone/Umeclidin/Vilanter24$15,646
ValacyclovirValacyclovir Hcl16$2,880
Doxycycline Hyclate175$1,940
Methylprednisolone229$1,667
PaxlovidNirmatrelvir/Ritonavir17$1,429
Atorvastatin Calcium92$1,403
Albuterol Sulfate HfaAlbuterol Sulfate53$1,289
Levothyroxine Sodium116$994
Escitalopram Oxalate87$982
Rosuvastatin Calcium63$952
Bupropion XlBupropion Hcl39$912

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$48$48,29137 claims
PfizerEliquis, Paxlovid$94$31,32941 claims
AstraZenecaFarxiga$285$22,16717 claims
Novo NordiskOzempic$215$16,84714 claims
GSKTrelegy Ellipta$20$15,64624 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 846 physician assistant providers in Alabama.

Other physician assistant in Gulf Shores

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →